Clinical Outcomes From NOCD Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention

Obsessive-Compulsive Disorder Clinical Trial

Official title:

Clinical Outcomes From NOCD Digital Behavioral Health Treatment of Obsessive-Compulsive Disorder Using Exposure and Response Prevention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04701372
• Other study ID #: NOCD001
• Status: Completed
• Start date: January 1, 2020
• Est. completion date: November 8, 2020

Study information

• Verified date: January 2021
• Source: NOCD
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a naturalistic, observational study of individuals with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy, augmented with between-session support with text messaging and an online community forum.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2069
• Est. completion date: November 8, 2020
• Est. primary completion date: November 8, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years and older

Eligibility

Inclusion Criteria:

• obsessive-compulsive disorder

Exclusion Criteria:

• none

Related Conditions & MeSH terms

• Obsessive-Compulsive Disorder

Intervention

Behavioral:
• Exposure and response prevention therapy
Exposures and response prevention therapy (a type of cognitive-behavioral therapy for obsessive-compulsive disorder), delivered in real-time by licensed therapists remotely via video. The treatment was augmented by between-session text messaging and online community support.

Locations

Country	Name	City	State
United States	Nocd, Llc	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
NOCD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dimensional Obsessive-Compulsive Scale	self-rated psychometric instrument to measure symptom severity of multiple OCD subtypes	change from pre-treatment to post-treatment (after 11 weeks)
Secondary	Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND) OCD severity scale	clinician-rated psychometric instrument to measure overall OCD symptom severity	pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)
Secondary	Depression Anxiety and Stress Scale (DASS-21)	self-rated psychometric instrument to measure depression, anxiety, and stress	pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)
Secondary	Quality of Life Enjoyment and Satisfaction Questionnaire -- Short Form (QLES-Q)	self-rated psychometric instrument to measure quality of life	pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)